Table 5.
Individual logistic regression models for each Quatro product examining associations between participant characteristics and choice of product for use in Month 5
| Separate model for each of the following: | Choice product | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ring | Insert | Film | Gel | |||||||||
| N = 180 | N = 180 | N = 180 | N = 180 | |||||||||
| % | AOR | 95% CI | % | AOR | 95% CI | % | AOR | 95% CI | % | AOR | 95% CI | |
| Country, Zimbabwe versus South Africa | 57 | 1.07 | (0.58 to 2.06) | 39 | 0.43 | (0.21 to 0.85) | 80 | 5.80 | (2.71 to 12.40) | 25 | 0.23 | (0.09 to 0.58) |
| Age group, 25 to 30 versus 18 to 24 years old | 39 | 0.95 | (0.48 to 1.86) | 30 | 0.61 | (0.29 to 1.26) | 45 | 1.07 | (0.53 to 2.16) | 48 | 2.00 | (0.85 to 4.72) |
| Married or living with partner | 53 | 0.56 | (0.15 to 2.12) | 43 | 1.31 | (0.37 to 4.67) | 81 | 2.34 | (0.59 to 9.30) | 28 | 0.55 | (0.11 to 2.60) |
| Parous | 88 | 1.30 | (0.44 to 3.85) | 85 | 1.31 | (0.47 to 3.69) | 96 | 1.65 | (0.33 to 8.33) | 69 | 0.48 | (0.17 to 1.37) |
| Completed secondary school | 73 | 1.33 | (0.64 to 2.76) | 70 | 0.99 | (0.47 to 2.09) | 62 | 0.87 | (0.42 to 1.80) | 69 | 0.77 | (0.31 to 1.91) |
| Earns income | 41 | 1.57 | (0.75 to 3.28) | 23 | 0.60 | (0.26 to 1.37) | 42 | 0.72 | (0.34 to 1.53) | 31 | 1.74 | (0.64 to 4.74) |
| Never/rarely attends religious service | 12 | 0.62 | (0.21 to 1.80) | 21 | 1.08 | (0.42 to 2.79) | 6 | 0.77 | (0.19 to 3.16) | 31 | 1.71 | (0.62 to 4.72) |
| Has place for privacy in home | 96 | 1.78 | (0.37 to 8.62) | 91 | 0.69 | (0.19 to 2.56) | 94 | 0.85 | (0.19 to 3.71) | 93 | 0.96 | (0.19 to 4.96) |
| Food worry past four weeks | 31 | 1.09 | (0.52 to 2.32) | 30 | 0.66 | (0.30 to 1.45) | 25 | 1.33 | (0.56 to 3.12) | 41 | 1.11 | (0.46 to 2.70) |
| Worried about HIV | 49 | 0.79 | (0.41 to 1.52) | 57 | 1.55 | (0.77 to 3.11) | 47 | 0.64 | (0.31 to 1.29) | 59 | 1.50 | (0.64 to 3.49) |
| Any intravaginal practices past three months | 84 | 0.75 | (0.30 to 1.91) | 85 | 0.99 | (0.37 to 2.63) | 91 | 1.20 | (0.39 to 3.71) | 86 | 1.28 | (0.39 to 4.26) |
| Contraceptive methods ever used | ||||||||||||
| Male condom | 80 | 1.55 | (0.65 to 3.70) | 79 | 0.75 | (0.30 to 1.89) | 58 | 0.51 | (0.23 to 1.12) | 97 | 6.35 | (0.79 to 51.34) |
| Implants | 45 | 2.24 | (1.08 to 4.66) | 21 | 0.61 | (0.27 to 1.40) | 36 | 0.69 | (0.32 to 1.47) | 24 | 0.98 | (0.36 to 2.70) |
| Injectable | 51 | 1.08 | (0.54 to 2.18) | 62 | 1.50 | (0.72 to 3.12) | 38 | 0.87 | (0.41 to 1.81) | 52 | 0.59 | (0.24 to 1.43) |
| Pills | 61 | 0.93 | (0.41 to 2.12) | 53 | 1.16 | (0.51 to 2.67) | 75 | 0.94 | (0.37 to 2.42) | 45 | 0.95 | (0.36 to 2.50) |
| Knew about product at enrolment | 55 | 2.30 | (0.59 to 8.98) | 23 | 1.12 | (0.37 to 3.35) | 49 | 0.63 | (0.26 to 1.53) | 21 | 0.38 | (0.10 to 1.39) |
| Told partner about product during crossover | 75 | 1.11 | (0.48 to 2.56) | 64 | 1.06 | (0.48 to 2.33) | 72 | 0.44 | (0.16 to 1.23) | 62 | 1.78 | (0.69 to 4.58) |
| Sex during crossover month, >4 times | 65 | 1.51 | (0.54 to 4.28) | 50 | 1.55 | (0.56 to 4.29) | 77 | 1.23 | (0.43 to 3.52) | 31 | 0.48 | (0.16 to 1.45) |
All models controlled for country and crossover month of use. Bold text indicates significance at p < 0.05. AOR, adjusted odds ratio; CI, confidence interval.